CURRENT FDA STANDING
MOTS-c legal status and what the FDA review means
MOTS-c remains a lab substance, without an approved use as medicine. An FDA group discussed it on July 23–24, 2026, and made no decision.
What the current FDA standing means for you
MOTS-c appeared on the FDA schedule for a public meeting on July 23–24, 2026 [18]. The advisers were asked whether a pharmacy preparing medicine for a single named person may begin with this ingredient, but a meeting date wasn’t a ruling or a change in MOTS-c’s standing for you. The discussion gave no pharmacy permission and cleared no product. For you, the key fact is that MOTS-c remains a lab substance without approval as a medicine or dietary supplement.
What the FDA has cleared for people
Built from sixteen linked parts, MOTS-c is a research peptide. No illness has a cleared MOTS-c treatment. There is no finished MOTS-c product or dose for people.
One federal rule covers a one-patient drug tied to a prescription bearing that patient’s name. A pharmacy may use a raw starting ingredient in only three cases [16]. An official rulebook may set its strength and purity, the ingredient may already be used in a cleared drug, or it may appear on an FDA allowed list. Pharmacists and doctors can review a request when none of those paths fits [16].
The FDA sent MOTS-c to that group for review [18]. For you, a review does not place MOTS-c on the allowed list or permit pharmacy use. The FDA page does not settle where MOTS-c stands under the one-person rule. It says only that a public talk was planned [18].
What the July 2026 agenda named
The FDA agenda named MOTS-c for a July 23–24, 2026 meeting of pharmacy advisers [18][16]. The group considered whether pharmacies could start with MOTS-c when making medicine for one person. One form was MOTS-c by itself; the other joined it to acetate, a salt used in some drug products. The agenda also named BPC-157 and TB-500, two unrelated lab substances, plus another one [18].
The advisers give an opinion, and the FDA decides later through a public rule process [16]. The meeting didn’t place MOTS-c on the allowed ingredient list or change its standing [18]. A meeting date can’t tell you what the later answer will be. I read the agenda as an open question.
What each pharmacy rule lets a site do
Federal law has two main parts for drugs made by pharmacies. One covers a drug for one named patient, made by a licensed pharmacy, a doctor with a valid prescription, or a federal clinic [16]. The other covers a larger drug-making facility that signs up for FDA checks and can prepare bigger batches [16]. It isn’t your usual local pharmacy.
For one-person work, a pharmacy may start with a raw ingredient when one of the listed tests is met [16][17]. An official rulebook may set its purity and strength. The ingredient may already appear in a cleared drug, or the FDA may add it to the allowed list [16]. A review does not clear a finished drug, and MOTS-c has neither a finished-drug approval nor a settled spot on that list [16][18]. If the FDA finds a grave safety risk, normal pharmacy use is barred while that finding stands [17].
What must happen before a pharmacy makes a drug
A licensed doctor first examines one patient and decides whether a drug made just for that patient fits [19]. A valid prescription then goes to a state-licensed pharmacy that follows the one-person rule. A larger facility can prepare bigger batches after signing up for added FDA checks [19]. The law must still allow the raw ingredient.
A visit may start by phone or video, but the doctor still has to make a real medical judgment [19]. A remote visit does not change which ingredients are allowed [19]. The pharmacy must follow the rule for its kind of work, and the FDA may stop normal use after finding a serious safety risk [19]. A lawyer or doctor familiar with your case can explain the rules to you.
What athletes need to watch for
The groups that police drug use in national and world sport prohibit MOTS-c throughout the year. They place it with banned peptides and substances that alter the way your body gets energy from food. Use can bring a top-level athlete a penalty. That sports rule stands apart from the FDA pharmacy question, and the study findings don’t change it.